Rezolute, Inc. (RZLT)
After hours:
| Previous close | 2.6000 |
| Open | 2.6500 |
| Bid | 2.6000 x 300 |
| Ask | 2.6600 x 100 |
| Day's range | 2.5350 - 2.7101 |
| 52-week range | 0.7200 - 3.6900 |
| Volume | |
| Avg. volume | 343,723 |
| Market cap | 106.739M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1000 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.67 |
GlobeNewswirePhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be
Simply Wall St.Rezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying
Rezolute, Inc. ( NASDAQ:RZLT ) insiders who bought shares over the past year were rewarded handsomely last week. The...
GlobeNewswireRezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Effects of RZ358 on Ligand-Induced Insulin Receptor Activation in U2OS-INSRa Cells Effects of RZ358 on Ligand-Induced Insulin Receptor Activation in U2OS-INSRa Cells REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed t
